WallStSmart

Esperion Therapeutics Inc (ESPR)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 4048% more annual revenue ($17.35B vs $418.24M). TEVA leads profitability with a 9.0% profit margin vs -1.8%. TEVA earns a higher WallStSmart Score of 66/100 (B-).

ESPR

Avoid

32

out of 100

Grade: F

Growth: 7.3Profit: 3.5Value: 5.0Quality: 5.5
Piotroski: 2/9Altman Z: -3.93

TEVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 6.3Quality: 4.0
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ESPR2 strengths · Avg: 9.0/10
Debt/EquityHealth
-0.8210/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
23.2%8/10

Revenue surging 23.2% year-over-year

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.858/10

Growing faster than its price suggests

Areas to Watch

ESPR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$805.76M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-260.8%2/10

ROE of -260.8% — below average capital efficiency

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
25.8x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ESPR

The strongest argument for ESPR centers on Debt/Equity, Revenue Growth. Revenue growth of 23.2% demonstrates continued momentum.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bear Case : ESPR

The primary concerns for ESPR are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Key Dynamics to Monitor

ESPR profiles as a growth stock while TEVA is a value play — different risk/reward profiles.

ESPR carries more volatility with a beta of 1.07 — expect wider price swings.

ESPR is growing revenue faster at 23.2% — sustainability is the question.

ESPR generates stronger free cash flow (-28M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (66/100 vs 32/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Esperion Therapeutics Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?